GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
Saved in:
Main Authors: | Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Clinical Diabetes and Healthcare |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcdhc.2024.1530811/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01) -
One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01) -
Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01) -
The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01) -
Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes
by: Kevin Y. Heo, BS, et al.
Published: (2024-12-01)